Defining blood pressure goals: Is it enough to manage total cardiovascular risk?

Journal of Hypertension

Volumn 27, Issue SUPPL. 5, 2009, Pages

  Mancia, Giuseppe ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

Angiotensin II receptor blockers; Antihypertensive therapy; Blood pressure goals; Cardiovascular risk; Hypertension; Telmisartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEART DEATH; HEART PROTECTION; HOME; HUMAN; HYPERTENSION; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 70349283277     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000357902.93951.3a     Document Type: Review

References (37)

1. Wolf-Maier K. Cooper R.S. Banegas J.R. Giampaoli S. Hense H.-W. Joffres M. Kastarinen M. Poulter N. Primatesta P. Rodriguez-Artalejo F. Stegmayr B. Thamm M. Tuomilehto J. Vanuzzo D. Vescio F. Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States Journal of the American Medical Association 2003 289 18 2363-2369 DOI 10.1001/jama.289.18.2363 1 Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289:2363-2369. (Pubitemid 37430168)
2. Martiniuk A.L. Lee C.M. Lawes C.M.M. Ueshima H. Suh I. Lam T.H. Gu D. Feigin V. Jamrozik K. Ohkubo T. Woodward M. Hypertension: Its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region Journal of Hypertension 2007 25 1 73-79 DOI 10.1097/HJH.0b013e328010775f, PII 0000487220070100000012 2 Martiniuk AL, Lee CM, Lawes CM, Ueshima H, Suh I, Lam TH, et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens 2007; 25:73-79. (Pubitemid 44885666)
3. Kearney P.M. Whelton M. Reynolds K. Muntner P. Whelton P.K. He J. Global burden of hypertension: Analysis of worldwide data Lancet 2005 365 9455 217-223 DOI 10.1016/S0140-6736(05)17741-1, PII S0140673605177411 3 Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223. (Pubitemid 40138015)
4. Maneia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462-1536.
5. Ezzati M. Lopez A.D. Rodgers A. Vander Hoorn S. Murray C.J.L. Selected major risk factors and global and regional burden of disease Lancet 2002 360 9343 1347-1360 DOI 10.1016/S0140-6736(02)11403-6 5 Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360. (Pubitemid 35341298)
6. MacMahon S, Peto R, Cutler J, Collins R, Sortie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1 : Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias, Lancet 1990; 335:765-774.
7. Lewington S. Clarke R. Qizilbash N. Peto R. Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies Lancet 2002 360 9349 1903-1913 DOI 10.1016/S0140-6736(02)11911-8 7 Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913. (Pubitemid 35472129)
8. Lenfant C, Roccella EJ. A call to action for more aggressive treatment of hypertension. J Hypertens 1999; 17 (Suppl):S3-S7.
9. Levy D. Larson M.G. Vasan R.S. Kannel W.B. Ho K.K.L. The progression from hypertension to congestive heart failure Journal of the American Medical Association 1996 275 20 1557-1562 DOI 10.1001/jama.275.20.1557 9 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562. (Pubitemid 26154241)
10. Klag M.J. Whelton P.K. Randall B.L. Neaton J.D. Brancati F.L. Ford C.E. Shulman N.B. Stamler J. Blood pressure and end-stage renal disease in men New England Journal of Medicine 1996 334 1 13-18 DOI 10.1056/NEJM199601043340103 10 Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. W Engl J Med 1996; 334:13-18. (Pubitemid 26012498)
11. Turnbull F. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials Archives of Internal Medicine 2005 165 12 1410-1419 http://archinte.ama-assn.org/cgi/ reprint/165/12/1410.pdf DOI 10.1001/archinte.165.12.1410 11 Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410-1419. (Pubitemid 40973424)
12. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials Lancet 2003 362 9395 1527-1535 DOI 10.1016/S0140-6736(03) 14739-3 12 Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535. (Pubitemid 37410190)
13. Mancia G. Messerli F. Bakris G. Zhou Q. Champion A. Pepine C.J. Blood pressure control and improved cardiovascular outcomes in the international verapamil SR-trandolapril study Hypertension 2007 50 2 299-305 DOI 10.1161/HYPERTENSIONAHA.107.090290, PII 0000426820070800000009 13 Maneia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50:299-305. (Pubitemid 47205777)
14. Collins R. MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease British Medical Bulletin 1994 50 2 272-298 14 Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-298. (Pubitemid 24165020)
15. Arima H. Chalmers J. Woodward M. Anderson C. Rodgers A. Davis S. MacMahon S. Neal B. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: The PROGRESS trial Journal of Hypertension 2006 24 6 1201-1208 DOI 10.1097/01.hjh.0000226212.34055.86, PII 0000487220060600000031 15 Artma H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24:1201-1208. (Pubitemid 43772329)
16. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36:646-661.
17. Bakris GL The importance of blood pressure control in the patient with diabetes. Am J Med 2004; 116 (Suppl 5A):30S-38S.
18. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
19. Berl T. Hunsicker L.G. Lewis J.B. Pfeffer M.A. Porush J.G. Rouleau J.-L. Drury P.L. Esmatjes E. Hricik D. Parikh C.R. Raz I. Vanhille P. Wiegmann T.B. Wolfe B.M. Locatelli F. Goldhaber S.Z. Lewis E.J. Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy Annals of Internal Medicine 2003 138 7 542-549+I43 19 Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the lrbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138:542-549. (Pubitemid 38124675)
20. Estacio R.O. Jeffers B.W. Gifford N. Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 2000 23 SUPPL. 2 B54-B64 20 Estacio RO, Jeffers BW, Gifford N, Schríer RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl 2): B54-B64. (Pubitemid 30185779)
21. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of Perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840.
22. Pepine C.J. Handberg E.M. Cooper-DeHoff R.M. Marks R.G. Kowey P. Messerli F.H. Mancia G. Cangiano J.L. Garcia-Barreto D. Keltai M. Erdine S. Bristol H.A. Kolb H.R. Bakris G.L. Cohen J.D. Parmley W.W. A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Treatment Strategy for Patients with Coronary Artery Disease the International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial Journal of the American Medical Association 2003 290 21 2805-2816 DOI 10.1001/jama.290.21.2805 22 Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816. (Pubitemid 37509488)
23. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
24. Nissen S.E. Tuzcu E.M. Libby P. Thompson P.D. Ghali M. Garza D. Berman L. Shi H. Buebendorf E. Topol E.J. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: A randomized controlled trial Journal of the American Medical Association 2004 292 18 2217-2226 DOI 10.1001/jama.292.18.2217 24 Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study - a randomized controlled trial. JAMA 2004; 292:2217-2225. (Pubitemid 39473159)
25. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
26. MacMahon S. Neal B. Tzourio C. Rodgers A. Woodward M. Cutler J. Anderson C. Chalmers J. Ohkubo T. Bouser M.G. Davis S. Donnan G. Hansson L. Harrap S. Lees K.R. Liu L. Mancia G. Neal B. Omae T. Reid J. Rodgers A. Sega R. Terent A. Tzourio C. Warlow C. Woodward M. Anderson N. Bladin C. Chambers B. Gordon G. Sharpe N. Collins R. Sandercock P. Simes J. Sleight P. Brnabic A. Colman S. Francis L. Lee A. Gong L. Bousser M.-G. Yamaguchi T. Lees K.R. William F. Deng Q. Hu D.X. Wang W. Wu A.L. Ma L.Y. Tao Z.Y. Biousse V. Berthet K. Ben Slamia L. Le Denmat C. Crespi S. Foglia G. Fujimoto C. Matsumura S. Marttala K. Pettersson M. Safwenberg M. Fenton J. McIlvenna Y. Currie R. Bartram H. Briad J. Clague A. Cleverly Y. Cosson M. Culpan A. Douglas D. Flett S. Gray B. Holloway T. Milne A. Prasad R. Ratnasabapathy Y. Santos A. Wills M. Agnew T. Chapman N. Lewis N. Mullane B. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 2001 358 9287 1033-1041 DOI 10.1016/S0140-6736(01)06178-5 26 PROGRESS Collaborative Study Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 ; 358:1033-1041. (Pubitemid 32925123)
27. PATS Collaborating Group. Poststroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med J 1995; 108:710-717.
28. Sega R. Facchetti R. Bombelli M. Cesana G. Corrao G. Grassi G. Mancia G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study Circulation 2005 111 14 1777-1783 DOI 10.1161/01.CIR.0000160923.04524.5B 28 Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monítorate e Loro Assocíazíoni (PAMELA) study. Circulation 2005; 111:1777-1783. (Pubitemid 40525142)
29. Mancia G. Bombelli M. Facchetti R. Madotto F. Corrao G. Trevano F.Q. Grassi G. Sega R. Long-term prognostic value of blood pressure variability in the general population: Results of the Pressioni Arteriose Monitorate e Lassociazioni Study Hypertension 2007 49 6 1265-1270 DOI 10.1161/ HYPERTENSIONAHA.107.088708 29 Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriöse Monítorate e Loro Assocíazioni Study. Hypertension 2007; 49:1265-1270. (Pubitemid 46809367)
30. Kario K. Pickering T.G. Umeda Y. Hoshide S. Hoshide Y. Morinari M. Murata M. Kuroda T. Schwartz J.E. Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study Circulation 2003 107 10 1401-1406 DOI 10.1161/01.CIR.0000056521.67546.AA 30 Karto K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107:1401-1406. (Pubitemid 36350739)
31. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-h blood pressure control: meta-analysis of a clinical database. J Clin Hypertens (Greenwich) 2003; 5:58-63.
32. Sharma AM, Davidson JA, Gavin JR III, DeSousa NJ. Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs valsartan/ hydrochlorothiazide in high-risk overweight/obese patients with hypertension and type 2 diabetes. Hypertension 2005; 46:898-899.
33. Mancia G. Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials Journal of Hypertension 2002 20 8 1461-1464 DOI 10.1097/00004872-200208000-00001 33 Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20:1461-1464. (Pubitemid 34921162)
34. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
35. Mancia G. Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: A meta-analysis Journal of Hypertension 2004 22 3 435-445 DOI 10.1097/00004872-200403000-00001 35 Maneia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens 2004; 22:435-445. (Pubitemid 38368472)
36. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62:443-462.
37. Dahlof B. Sever P.S. Poulter N.R. Wedel H. Beevers D.G. Caulfield M. Collins R. Kjeldsen S.E. Kristinsson A. McInnes G.T. Mehlsen J. Nieminen M. O'Brien E. Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial Lancet 2005 366 9489 895-906 DOI 10.1016/S0140-6736(05)67185-1, PII S0140673605671851 37 Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding Perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906. (Pubitemid 41265663)